Reduced 123I-MIBG uptake in the parotid and submandibular glands in patients with Parkinson's disease identified using a quantitative semi-automatic method

J Neurol. 2023 Sep;270(9):4385-4392. doi: 10.1007/s00415-023-11770-7. Epub 2023 May 24.

Abstract

Objectives: To analyze 123I-metaiodobenzylguanidine (MIBG) uptake in the parotid and submandibular glands in patients with Parkinson's disease (PD) in comparison with controls, and to compare MIBG uptake between those glands and the myocardium. Furthermore, we aimed to identify the relationships between clinical features and MIBG uptake.

Methods: We recruited 77 patients with PD and 21 age-matched controls. We assessed MIBG scintigraphy in the major salivary glands and myocardium. We calculated the MIBG uptake ratio in the parotid glands/mediastinum (P/M), submandibular glands/mediastinum (S/M), and heart/mediastinum (H/M) using a quantitative semi-automatic method. We investigated the correlations between MIBG uptake and clinical features.

Results: The P/M and H/M ratios in the early and delayed phases were significantly reduced in PD patients compared to controls, while the delayed phase S/M ratio was reduced in PD patients compared to controls. The P/M ratio correlated with the S/M ratio, while neither the P/M nor S/M ratio correlated with the H/M ratio. Between PD patients and controls, sensitivity and specificity were 54.8% and 59.1% for the delayed phase P/M ratio, while sensitivity and specificity were 59.5% and 61.0% for the delayed phase S/M ratio, respectively. Furthermore, sensitivity and specificity for the delayed phase H/M ratio were 85.7% and 79.2, respectively.

Conclusion: MIBG uptake in the parotid and submandibular glands was reduced in patients with PD. Furthermore, sympathetic denervation in the major salivary glands and myocardium might progress independently. Our findings suggest a new aspect of the pathological distribution of PD.

Keywords: Autonomic dysfunction; MIBG scintigraphy; Major salivary glands; Myocardium; Parkinson’s disease.

MeSH terms

  • 3-Iodobenzylguanidine*
  • Heart / diagnostic imaging
  • Humans
  • Parkinson Disease* / diagnostic imaging
  • Parotid Gland
  • Radiopharmaceuticals
  • Submandibular Gland / diagnostic imaging

Substances

  • 3-Iodobenzylguanidine
  • Iodine-123
  • Radiopharmaceuticals